An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
KRAS-driven cancers remain refractory to current clinical therapies. In this study, the authors show that lung and pancreatic cancers expressing oncogenic KRAS can be targeted by genetic inhibition of FOSL1, which involves downregulation of genes of the mitotic machinery.
Guardado en:
Autores principales: | Adrian Vallejo, Naiara Perurena, Elisabet Guruceaga, Pawel K. Mazur, Susana Martinez-Canarias, Carolina Zandueta, Karmele Valencia, Andrea Arricibita, Dana Gwinn, Leanne C. Sayles, Chen-Hua Chuang, Laura Guembe, Peter Bailey, David K. Chang, Andrew Biankin, Mariano Ponz-Sarvise, Jesper B. Andersen, Purvesh Khatri, Aline Bozec, E. Alejandro Sweet-Cordero, Julien Sage, Fernando Lecanda, Silve Vicent |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b67e9794d6104499b87c9422aa01ff4a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of FOSL1 in stem-like cell reprogramming processes
por: Valeria Pecce, et al.
Publicado: (2021) -
Fosl1 is vital to heart regeneration upon apex resection in adult Xenopus tropicalis
por: Hai-Yan Wu, et al.
Publicado: (2021) -
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020) -
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
por: Naiara Santana-Codina, et al.
Publicado: (2018) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Jieqiong Wang, et al.
Publicado: (2016)